INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Jasper Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On July 7, 2025, Jasper Therapeutics released updated data from its BEACON Phase 1b/2a study of briquilimab, indicating issues with a specific drug product lot that affected results in certain patient cohorts [3] - The stock price of Jasper Therapeutics fell by $3.73 per share, or 55.1%, closing at $3.04 per share following the announcement of the study results [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]